JP2017002083A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017002083A5 JP2017002083A5 JP2016196955A JP2016196955A JP2017002083A5 JP 2017002083 A5 JP2017002083 A5 JP 2017002083A5 JP 2016196955 A JP2016196955 A JP 2016196955A JP 2016196955 A JP2016196955 A JP 2016196955A JP 2017002083 A5 JP2017002083 A5 JP 2017002083A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- individual
- nanoparticles
- blood vessels
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 62
- 210000004204 blood vessel Anatomy 0.000 claims 16
- 239000002105 nanoparticle Substances 0.000 claims 15
- 102000009027 Albumins Human genes 0.000 claims 9
- 108010088751 Albumins Proteins 0.000 claims 9
- 238000002347 injection Methods 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 9
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 9
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 9
- 229960002930 sirolimus Drugs 0.000 claims 9
- 210000001367 artery Anatomy 0.000 claims 6
- 230000002792 vascular Effects 0.000 claims 6
- 206010016654 Fibrosis Diseases 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000007634 remodeling Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 210000001147 pulmonary artery Anatomy 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 210000001627 cerebral artery Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 238000013152 interventional procedure Methods 0.000 claims 1
- 208000030175 lameness Diseases 0.000 claims 1
- 210000002414 leg Anatomy 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 210000002254 renal artery Anatomy 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161518084P | 2011-04-28 | 2011-04-28 | |
| US61/518,084 | 2011-04-28 | ||
| US201161557851P | 2011-11-09 | 2011-11-09 | |
| US61/557,851 | 2011-11-09 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508146A Division JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157942A Division JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017002083A JP2017002083A (ja) | 2017-01-05 |
| JP2017002083A5 true JP2017002083A5 (enExample) | 2017-02-16 |
| JP6196719B2 JP6196719B2 (ja) | 2017-09-13 |
Family
ID=47072793
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508146A Active JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2016196955A Active JP6196719B2 (ja) | 2011-04-28 | 2016-10-05 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2017157942A Active JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2018203038A Pending JP2019011378A (ja) | 2011-04-28 | 2018-10-29 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508146A Active JP6038123B2 (ja) | 2011-04-28 | 2012-04-27 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157942A Active JP6427641B2 (ja) | 2011-04-28 | 2017-08-18 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP2018203038A Pending JP2019011378A (ja) | 2011-04-28 | 2018-10-29 | ナノ粒子組成物の脈管内送達およびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US9061014B2 (enExample) |
| EP (1) | EP2701731B1 (enExample) |
| JP (4) | JP6038123B2 (enExample) |
| KR (3) | KR20200051841A (enExample) |
| CN (3) | CN109288789A (enExample) |
| AU (2) | AU2012249371B2 (enExample) |
| BR (1) | BR112013027674A2 (enExample) |
| CA (2) | CA2834040C (enExample) |
| ES (1) | ES2819204T3 (enExample) |
| IL (2) | IL229041B (enExample) |
| MX (1) | MX354216B (enExample) |
| SG (2) | SG194623A1 (enExample) |
| WO (1) | WO2012149451A1 (enExample) |
| ZA (1) | ZA201307875B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6302875B1 (en) | 1996-10-11 | 2001-10-16 | Transvascular, Inc. | Catheters and related devices for forming passageways between blood vessels or other anatomical structures |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US10441747B2 (en) | 2002-01-22 | 2019-10-15 | Mercator Medsystems, Inc. | Methods and systems for inhibiting vascular inflammation |
| US9636174B2 (en) | 2002-04-08 | 2017-05-02 | Medtronic Ardian Luxembourg S.A.R.L. | Methods for therapeutic renal neuromodulation |
| US7617005B2 (en) | 2002-04-08 | 2009-11-10 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US8150519B2 (en) | 2002-04-08 | 2012-04-03 | Ardian, Inc. | Methods and apparatus for bilateral renal neuromodulation |
| US20080213331A1 (en) | 2002-04-08 | 2008-09-04 | Ardian, Inc. | Methods and devices for renal nerve blocking |
| US20070135875A1 (en) | 2002-04-08 | 2007-06-14 | Ardian, Inc. | Methods and apparatus for thermally-induced renal neuromodulation |
| US20070129761A1 (en) | 2002-04-08 | 2007-06-07 | Ardian, Inc. | Methods for treating heart arrhythmia |
| CN101076290B (zh) | 2004-12-09 | 2011-11-23 | 铸造品股份有限公司 | 主动脉瓣修复 |
| WO2006089290A1 (en) | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2012201568B2 (en) * | 2005-02-18 | 2014-07-31 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| US8399443B2 (en) | 2009-04-22 | 2013-03-19 | Mercator Medsystems, Inc. | Treatment of hypertension by renal vascular delivery of guanethidine |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| EP2694150A1 (en) | 2011-04-08 | 2014-02-12 | Covidien LP | Iontophoresis drug delivery system and method for denervation of the renal sympathetic nerve and iontophoretic drug delivery |
| BR112013027674A2 (pt) | 2011-04-28 | 2016-09-06 | Abraxis Bioscience Llc | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". |
| PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| DK2964329T3 (da) | 2013-03-08 | 2020-03-16 | Univ California | Polyphosphat-funktionaliserede uorganiske nanopartikler som hæmostatiske sammensætninger og anvendelsesfremgangsmåder |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| WO2016065245A1 (en) | 2014-10-24 | 2016-04-28 | Incept, Llc | Extra luminal scaffold |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EP3313401B1 (en) | 2015-06-29 | 2021-10-06 | Abraxis BioScience, LLC | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| EP4295906A3 (en) * | 2016-09-22 | 2024-02-21 | Mercator Medsystems, Inc. | Treatment of restenosis using temsirolimus |
| CN110022876A (zh) * | 2016-09-28 | 2019-07-16 | 阿布拉科斯生物科学有限公司 | 治疗线粒体和代谢病症的方法 |
| AU2018272061A1 (en) | 2017-05-26 | 2020-01-02 | Mercator Medsystems, Inc. | Combination therapy for treatment of restenosis |
| US11116561B2 (en) | 2018-01-24 | 2021-09-14 | Medtronic Ardian Luxembourg S.A.R.L. | Devices, agents, and associated methods for selective modulation of renal nerves |
| EP3765122B1 (en) | 2018-03-14 | 2024-10-09 | Mercator Medsystems, Inc. | Medical instrument and medical method for localized drug delivery |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| JP7335123B2 (ja) * | 2019-10-07 | 2023-08-29 | 株式会社日本触媒 | 樹脂組成物、硬化性組成物、塗膜付き物品、塗膜付き物品の製造方法、コーティング剤及び積層塗膜付き基材の製造方法 |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| JP3746293B2 (ja) | 1993-02-22 | 2006-02-15 | アメリカン バイオサイエンス、インコーポレイテッド | 生物製剤のインビボ送達の方法とそのための組成物 |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US8137684B2 (en) | 1996-10-01 | 2012-03-20 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| CN1331321A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人丝/苏氨酸蛋白激酶16.17和编码这种多肽的多核苷酸 |
| AU2002249958B2 (en) * | 2001-01-16 | 2007-11-08 | Vascular Therapies, Inc. | Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| US6547303B1 (en) | 2001-08-13 | 2003-04-15 | Johnson Controls Technology Company | Pivoting seating system |
| US6860867B2 (en) | 2001-09-20 | 2005-03-01 | The Regents Of The University Of California | Method of interventional surgery |
| US7744584B2 (en) | 2002-01-22 | 2010-06-29 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
| US20060189941A1 (en) * | 2002-01-22 | 2006-08-24 | Mercator Medsystems, Inc. | Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation |
| WO2003061731A2 (en) | 2002-01-22 | 2003-07-31 | Endobionics, Inc. | Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia |
| US20030207907A1 (en) | 2002-05-03 | 2003-11-06 | Iversen Patrick L. | Delivery of microparticle-conjugated drugs for inhibition of stenosis |
| DE10244847A1 (de) * | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
| JP2006515186A (ja) * | 2002-09-26 | 2006-05-25 | アンジオテック インターナショナル アクツィエン ゲゼルシャフト | 血管周囲ラップ |
| EP1585548B1 (en) | 2002-12-09 | 2018-06-27 | Abraxis BioScience, LLC | Compositions and methods of delivery of pharmacological agents |
| US20040213770A1 (en) | 2003-04-22 | 2004-10-28 | Endobionics, Inc. | Methods and systems for treating ischemic cardiac and other tissues |
| US8003122B2 (en) * | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
| WO2005112569A2 (en) | 2004-05-13 | 2005-12-01 | Medtronic Vascular, Inc. | Methods for compounding and delivering a therapeutic agent to the adventitia of a vessel |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US7727554B2 (en) * | 2004-12-21 | 2010-06-01 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Sustained-release nanoparticle compositions and methods for using the same |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| WO2006089290A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience Inc.. | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20080214595A1 (en) | 2005-05-16 | 2008-09-04 | Seigo Izumo | Use Of Rapamycin Derivatives For The Treatment And/Or Prevention Of Cardiovas Cular Disorders |
| CN101257861B (zh) * | 2005-06-21 | 2012-12-05 | 渗透治疗有限公司 | 用于增强血管通路的方法和组合物 |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| EP2056793A4 (en) * | 2006-07-31 | 2011-08-17 | Neurosystec Corp | NANOPARTICLES WITH FREE BASE OF GACYCLIDINE |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| PT2117520T (pt) | 2006-12-14 | 2018-12-04 | Abraxis Bioscience Llc | Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane |
| LT2481402T (lt) | 2007-03-07 | 2018-10-25 | Abraxis Bioscience, Llc | Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą |
| CN101730526A (zh) * | 2007-03-07 | 2010-06-09 | 阿布拉科斯生物科学有限公司 | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| US9044385B2 (en) * | 2007-05-16 | 2015-06-02 | Abbott Cardiovascular Systems Inc. | Therapeutic compositions for targeted vessel delivery |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CA2709712C (en) * | 2007-12-20 | 2016-05-10 | Surmodics Pharmaceuticals, Inc. | Process for preparing microparticles having a low residual solvent volume |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| BRPI1008955A2 (pt) | 2009-03-13 | 2015-09-01 | Abraxis Bioscience Llc | Terapia de combinação com derivados de tiocolchicina. |
| EP2416650B1 (en) | 2009-04-10 | 2020-02-26 | Abraxis BioScience, LLC | Nanoparticle formulations and uses therof |
| CN102460167B (zh) | 2009-04-15 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 不含朊病毒的纳米颗粒组合物和方法 |
| US8399443B2 (en) * | 2009-04-22 | 2013-03-19 | Mercator Medsystems, Inc. | Treatment of hypertension by renal vascular delivery of guanethidine |
| JP2013503174A (ja) | 2009-08-25 | 2013-01-31 | アブラクシス バイオサイエンス， エルエルシー | タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法 |
| CN104784121A (zh) | 2010-03-26 | 2015-07-22 | 阿布拉科斯生物科学有限公司 | 治疗肝细胞癌的方法 |
| NZ602385A (en) | 2010-03-29 | 2014-08-29 | Abraxis Bioscience Llc | Methods of treating cancer |
| WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
| EP3085387A1 (en) * | 2010-04-26 | 2016-10-26 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
| JP2013527232A (ja) | 2010-06-02 | 2013-06-27 | アブラクシス バイオサイエンス， エルエルシー | 膀胱がんの処置方法 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| MY166014A (en) | 2010-06-07 | 2018-05-21 | Abraxis Bioscience Llc | Combination therapy methods for treating proliferative diseases |
| BR112013027674A2 (pt) | 2011-04-28 | 2016-09-06 | Abraxis Bioscience Llc | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". |
| PT2790675T (pt) | 2011-12-14 | 2019-09-23 | Abraxis Bioscience Llc | Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| AU2014228386B2 (en) | 2013-03-13 | 2018-11-29 | Abraxis Bioscience, Llc | Methods of treatment of pediatric solid tumor |
| CA2903548A1 (en) | 2013-03-14 | 2014-09-25 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| WO2015157120A1 (en) | 2014-04-06 | 2015-10-15 | Abraxis Bioscience, Llc | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer |
| WO2016141365A1 (en) | 2015-03-05 | 2016-09-09 | Abraxis Bioscience, Llc | Method for treating cancer based on level of glucocorticoid receptor |
| CA2990726A1 (en) | 2015-06-29 | 2017-01-05 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy |
| JP2018527308A (ja) | 2015-06-29 | 2018-09-20 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物のためのバイオマーカー |
| EP3313401B1 (en) | 2015-06-29 | 2021-10-06 | Abraxis BioScience, LLC | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| EP3313409A4 (en) | 2015-06-29 | 2018-12-26 | Abraxis BioScience, LLC | Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy |
| US20170181988A1 (en) | 2015-12-23 | 2017-06-29 | Cipla Limited | Methods for the treatment of bladder cancer |
-
2012
- 2012-04-27 BR BR112013027674A patent/BR112013027674A2/pt not_active Application Discontinuation
- 2012-04-27 CN CN201811222358.3A patent/CN109288789A/zh active Pending
- 2012-04-27 AU AU2012249371A patent/AU2012249371B2/en active Active
- 2012-04-27 WO PCT/US2012/035626 patent/WO2012149451A1/en not_active Ceased
- 2012-04-27 EP EP12777153.3A patent/EP2701731B1/en active Active
- 2012-04-27 SG SG2013079264A patent/SG194623A1/en unknown
- 2012-04-27 MX MX2013012458A patent/MX354216B/es active IP Right Grant
- 2012-04-27 CA CA2834040A patent/CA2834040C/en active Active
- 2012-04-27 KR KR1020207012800A patent/KR20200051841A/ko not_active Ceased
- 2012-04-27 SG SG10201606406PA patent/SG10201606406PA/en unknown
- 2012-04-27 CN CN201280032010.2A patent/CN103648521A/zh active Pending
- 2012-04-27 US US14/113,568 patent/US9061014B2/en active Active
- 2012-04-27 CA CA3063641A patent/CA3063641A1/en not_active Abandoned
- 2012-04-27 CN CN201810882369.8A patent/CN109172809A/zh active Pending
- 2012-04-27 ES ES12777153T patent/ES2819204T3/es active Active
- 2012-04-27 JP JP2014508146A patent/JP6038123B2/ja active Active
- 2012-04-27 KR KR1020197010659A patent/KR102108959B1/ko active Active
- 2012-04-27 KR KR1020137031161A patent/KR101970342B1/ko active Active
-
2013
- 2013-10-22 ZA ZA2013/07875A patent/ZA201307875B/en unknown
- 2013-10-24 IL IL229041A patent/IL229041B/en active IP Right Grant
-
2015
- 2015-05-15 US US14/714,131 patent/US9884013B2/en not_active Expired - Fee Related
-
2016
- 2016-10-05 JP JP2016196955A patent/JP6196719B2/ja active Active
-
2017
- 2017-08-18 JP JP2017157942A patent/JP6427641B2/ja active Active
- 2017-09-06 AU AU2017225031A patent/AU2017225031B2/en active Active
- 2017-12-21 US US15/851,478 patent/US10258565B2/en active Active
-
2018
- 2018-10-29 JP JP2018203038A patent/JP2019011378A/ja active Pending
-
2019
- 2019-02-25 US US16/284,995 patent/US20190183789A1/en not_active Abandoned
-
2020
- 2020-01-28 IL IL272313A patent/IL272313A/en unknown
- 2020-06-12 US US16/900,565 patent/US20200306180A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515028A5 (enExample) | ||
| JP2020521755A5 (enExample) | ||
| JP2015518897A5 (enExample) | ||
| Liu et al. | Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial | |
| Kitamura et al. | Transient sinus node dysfunction following sinus node artery occlusion due to radiofrequency catheter ablation of the septal superior vena cava–right atrium junction | |
| de Gregorio et al. | Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease | |
| Al-Hijji et al. | Revascularization for left main and multivessel coronary artery disease: current status and future prospects after the EXCEL and NOBLE trials | |
| Ateş et al. | Acute coronary syndrome due to midazolam use: Kounis syndrome during a transurethral prostatectomy | |
| Tsuji | Four-year follow-up of the biodegradable stent (Igaki-Tamai stent) | |
| Colucci | Overview of the therapy of heart failure due to systolic dysfunction | |
| Koutouzis et al. | Percutaneous coronary intervention facilitated by extracorporeal membrane oxygenation support in a patient with cardiogenic shock | |
| Wei et al. | Giant right sinus of Valsalva aneurysm led to proximal right coronary artery occlusion. | |
| Gülşen et al. | Coronary vasospasm-induced periodic ventricular fibrillation and successful ablation through coronary stenting | |
| Biernawska et al. | Electrophysiological, hemodynamic, and metabolic response to open procedure or endovascular repair of infrarenal aortic aneurysms | |
| Allen | State of the Art in Cardiac Intervention: A Case Report | |
| Lee et al. | Cardiopulmonary resuscitation with assisted extracorporeal life support during cardiac arrest caused by drug-eluting stent thrombosis: a case report | |
| CN202843855U (zh) | 一种新型冠状动脉血管支架 | |
| Kolesnichenko et al. | Modeling L-name induced nitric oxide deficiency considering the the cardio-and endothelial protective effects | |
| Ngow et al. | Anterior Myocardial Infarction Associated with Myocardial Bridging in a Young Man | |
| Karabay et al. | Coronary muscular bridge mimicking acute stent thrombosis: online article | |
| de la Torre Hernandez et al. | Update on interventional cardiology | |
| Yamada et al. | Reply to letter to the editor:“A potential and lionhearted soldier for atrial fibrillation accompanied with heart failure: Renal denervation” | |
| Mangialavori et al. | Subclavian steal syndrome presenting as recurrent pulmonary oedema associated with acute left ventricular diastolic dysfunction | |
| Saxena et al. | Non-cardiac surgery 2 weeks after percutaneous cardiac intervention | |
| Kılıç et al. | A severe aortic coarctation newly diagnosed during cardiac catheterization in an adult presenting with acute anterior myocardial infarction |